HC Wainwright Reaffirms Buy Rating for Capricor Therapeutics (NASDAQ:CAPR)

HC Wainwright reiterated their buy rating on shares of Capricor Therapeutics (NASDAQ:CAPR) in a research note issued to investors on Wednesday, Benzinga reports. They currently have a $40.00 price objective on the biotechnology company’s stock.

A number of other brokerages have also weighed in on CAPR. Cantor Fitzgerald restated an overweight rating and issued a $8.00 price objective on shares of Capricor Therapeutics in a report on Friday, September 20th. Maxim Group upped their price target on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the company a buy rating in a report on Wednesday, September 25th. Finally, Oppenheimer reiterated an outperform rating and set a $15.00 price target on shares of Capricor Therapeutics in a report on Monday, September 23rd. One analyst has rated the stock with a sell rating and five have issued a buy rating to the company. According to MarketBeat.com, Capricor Therapeutics currently has an average rating of Moderate Buy and an average price target of $22.60.

Capricor Therapeutics Stock Performance

Shares of CAPR opened at $17.77 on Wednesday. The firm has a market cap of $578.24 million, a price-to-earnings ratio of -19.11 and a beta of 4.01. Capricor Therapeutics has a fifty-two week low of $2.68 and a fifty-two week high of $21.98. The firm has a 50 day moving average price of $7.44 and a 200-day moving average price of $6.07.

Capricor Therapeutics (NASDAQ:CAPR) last announced its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.03). The business had revenue of $3.97 million during the quarter, compared to the consensus estimate of $4.51 million. Capricor Therapeutics had a negative return on equity of 220.27% and a negative net margin of 102.93%. As a group, equities research analysts predict that Capricor Therapeutics will post -1.13 earnings per share for the current year.

Insider Buying and Selling at Capricor Therapeutics

In related news, major shareholder Shinyaku Co Ltd Nippon acquired 2,798,507 shares of Capricor Therapeutics stock in a transaction on Friday, September 20th. The shares were acquired at an average cost of $5.36 per share, with a total value of $14,999,997.52. Following the transaction, the insider now owns 7,090,351 shares in the company, valued at $38,004,281.36. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 12.00% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. SG Americas Securities LLC purchased a new position in Capricor Therapeutics during the 3rd quarter valued at $133,000. Marshall Wace LLP purchased a new position in Capricor Therapeutics during the 2nd quarter valued at $426,000. Renaissance Technologies LLC increased its position in Capricor Therapeutics by 158.7% during the 2nd quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company’s stock valued at $656,000 after purchasing an additional 84,350 shares during the period. Main Street Financial Solutions LLC increased its position in Capricor Therapeutics by 37.5% during the 2nd quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock valued at $131,000 after purchasing an additional 7,500 shares during the period. Finally, Rhumbline Advisers purchased a new stake in shares of Capricor Therapeutics in the 2nd quarter worth about $147,000. 21.68% of the stock is owned by hedge funds and other institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.